Alterity Therapeutics company info

What does Alterity Therapeutics do?
Alterity Therapeutics (ASX:ATH), (NASDAQ:ATHE) is a biotechnology company dedicated to developing and commercializing therapies to treat and improve the lives of patients suffering from neurodegenerative diseases, particularly Parkinson's disease and other movement disorders. Alterity's research focuses on creating novel drug candidates that can modify disease processes, aiming to halt or reverse the progression of these debilitating conditions. The company is pioneering efforts in identifying and targeting cellular mechanisms that are thought to be critical in the development and progression of neurological diseases. One of their flagship projects involves the development of ATH434, a small molecule drug designed to reduce the accumulation of pathological proteins implicated in neurodegeneration. Alterity Therapeutics' objectives include advancing its portfolio of drug candidates through clinical trials, securing partnerships for development and commercialization, and ultimately bringing new therapeutic options to patients and healthcare providers to address the unmet needs in neurodegenerative care.
Alterity Therapeutics company media
Company Snapshot

Is Alterity Therapeutics a public or private company?

key
Ownership
Public

How many people does Alterity Therapeutics employ?

people
Employees
11

What sector is Alterity Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for Alterity Therapeutics?

location pin
Head Office
Melbourne, Australia

What year was Alterity Therapeutics founded?

founded flag
Year Founded
1997
What does Alterity Therapeutics specialise in?
/Neurodegenerative Diseases /Drug Development /Therapeutic Solutions /Parkinson’s Research /Healthcare Biotechnology /Clinical Trials

What are the products and/or services of Alterity Therapeutics?

Overview of Alterity Therapeutics offerings
ATH434: A small molecule therapy developed to treat Parkinsonian disorders by reducing alpha-synuclein pathology and preserving neurons.
Research on neurodegenerative diseases focuses on identifying novel therapeutic targets for Parkinson's disease and related disorders.
Partnerships for drug development are aimed at advancing its portfolio of neuroprotective candidates for various neurodegenerative conditions.
Collaborations with academic institutions to understand the underlying mechanisms of neurodegeneration and to discover new drug candidates.
Patent portfolio management ensures the protection and commercialization of its innovative treatments for neurodegenerative diseases.
Community and patient outreach programs to raise awareness and provide support for those affected by Parkinson's disease and other neurological conditions.

Who is in the executive team of Alterity Therapeutics?

Alterity Therapeutics leadership team
  • Mr. Geoffrey Paul Kempler B.Sc.
    Mr. Geoffrey Paul Kempler B.Sc.
    Co-Founder & Non-Executive Chairman
  • Dr. David A. Stamler M.D.
    Dr. David A. Stamler M.D.
    Chief Executive Officer
  • Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A.
    Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A.
    CFO & Company Secretary
  • Dr. Rudolph Emile Tanzi Ph.D.
    Dr. Rudolph Emile Tanzi Ph.D.
    Chief Scientific Advisor and Member of Research & Development Advisory Board
  • Dr. Steven D. Targum
    Dr. Steven D. Targum
    Chief Medical Advisor
  • Dr. Robert  Cherny
    Dr. Robert Cherny
    Head of Research